RAMAT GAN, Israel--(BUSINESS WIRE)--Optimata Ltd. announced today that it has been granted U.S. Patent 7,418,374, entitled: “Treatment protocol generation for diseases related to angiogenesis”. The patent protects a system and methods for modeling diseases which relate to angiogenesis processes, and optimization methods to predict improved treatment regimens. Angiogenesis is a key process in the progression of different diseases such as solid tumor cancers, cardiovascular diseases, hematological disorders, and macular degeneration.
